(MIBG) WITH INTENSIVE CHEMOTHERYAPY AND AUTOLOGOUS STEM CELL RESCUE FOR NEUROBLA

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。神经母细胞瘤是儿童最常见的实体瘤之一。尽管现代化学疗法和放射疗法取得了进步，但目前大多数神经母细胞瘤患者的治愈率< 40%。那些对最初的化疗（称为诱导疗法）没有反应的患者，或者那些肿瘤复发的患者，治愈的机会甚至更低。这类患者的治愈率< 10%。这个方案的目的是治疗那些最有可能死于癌症的病人那些神经母细胞瘤复发的病人或者那些诱导治疗失败的病人。这些患者将接受一种名为131-I MIBG的放射性化学物质的治疗。人们希望MIBG能够将辐射特异地传递到肿瘤上，从而使身体的其他部位免受辐射的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Neuroblastomas are one of the most common solid tumors of childhood. Despite modern advances in chemotherapy and radiation therapy, the ability to cure most patients with neuroblastoma is currently < 40%. Patients who fail to respond to initial chemotherapy (called induction therapy), or those patients whose tumors relapse have even a much lower chance for cure. The cure rate for such patients is < 10%. The purpose of this protocol is to treat those patients with the greatest chance of dying from their cancer those patients with relapsed neuroblastoma or those who fail induction therapy. The patients will be treated with a radio-active chemical called 131-I MIBG. The hope is that the MIBG will deliver radiation specifically to the tumor, thereby sparing the rest of the body the effects of the radiation.